Press release
Primary Sclerosing Cholangitis Market Growth Fuels New Therapies | Key Players: Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb
Primary Sclerosing Cholangitis (PSC)
The Primary Sclerosing Cholangitis Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?jd
Primary Sclerosing Cholangitis Market Landscape Analysis:
The Primary Sclerosing Cholangitis market includes diagnostic tools, treatment therapies, and supportive care solutions for PSC, a chronic and progressive liver disease characterized by inflammation and fibrosis of the bile ducts. This market covers pharmaceuticals, clinical services, and pipeline developments focused on managing PSC and its complications.
Strategic Players Driving the Primary Sclerosing Cholangitis Market Forward:
The major global players in the market include Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Allergan, Genfit, Pliant Therapeutics, ChemomAb Therapeutics Ltd., and Dr. Falk Pharma, among others.
Primary Sclerosing Cholangitis Market Updates: Shifting Industry Trends and Market Potential
* A notable acquisition occurred with Intercept Pharmaceuticals acquiring a boutique biotech with novel anti-fibrotic compounds targeting PSC.
* Vertex Pharmaceuticals increased R&D funding specifically for pipeline candidates addressing rare liver diseases, including PSC.
* Joint ventures between academic research centers and pharma are accelerating clinical trials for PSC, with funding surpassing $100 million globally.
Research Methodology:
The global Primary Sclerosing Cholangitis Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.
Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/primary-sclerosing-cholangitis-market?jd
Segment Covered in the Primary Sclerosing Cholangitis Market:
Global Primary Sclerosing Cholangitis (PSC) Market is segmented by Treatment (Medication-based Therapies, Bile Duct Blockages, Liver Transplantation), By Disease Stage (Early-stage PSC, Moderate-stage PSC, Advanced-stage PSC), By Patient Age (Child (0-18), Adult (18 and above)), By End-User (Hospitals, Specialty Clinics, Others).
Regional Analysis for Primary Sclerosing Cholangitis Market:
United States:
The US market dominates due to higher disease awareness, advanced diagnostics, and increased investment in rare liver disease therapeutics. The US clinical trial infrastructure and biotech investments support leading R&D activity in PSC treatments. The demand for anti-fibrotic and immunomodulatory drugs is particularly strong.
Japan:
PSC is rarer but increasing in Japan, driven by better diagnostic practices and an aging population. However, the market is smaller and more niche relative to the US, with ongoing efforts to improve therapeutic options and clinical trial activity.
Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=primary-sclerosing-cholangitis-market?jd
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?jd
Most Frequently Asked Questions in the Primary Sclerosing Cholangitis Market Research Industry:
➠ Who leads the Primary Sclerosing Cholangitis industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Primary Sclerosing Cholangitis market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Primary Sclerosing Cholangitis market growth?
➠ What are the dominant sales and distribution strategies in the Primary Sclerosing Cholangitis industry?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market Growth Fuels New Therapies | Key Players: Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb here
News-ID: 4116742 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Germany Medical Technology market reached US$ 42.2 billion in 2023 and is expect …
The Germany Medical Technology market reached US$ 42.2 billion in 2023 and is expected to reach US$ 62.63 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031.
Germany's Medical Technology Market encompasses devices, diagnostic equipment, and digital health solutions. Growth is driven by aging populations, chronic disease prevalence, and healthcare innovation. Hospitals, clinics, and research centers are major end-users. Innovations focus on minimally invasive devices, AI…
Biopesticides Market Projected to Reach US$24.16B by 2032, Growing at a CAGR of …
The Biopesticides Market was valued at US$ 7,734.43 million in 2024 and is projected to reach US$ 24,158.10 million by 2032, registering a CAGR of 15.3% during the forecast period 2025-2032.
The market focuses on the development and use of biological pest control solutions derived from natural organisms, including microorganisms, plant extracts, and bioactive compounds. Biopesticides are widely applied in agriculture, horticulture, and forestry to control pests, enhance crop protection, and…
Japan Wearable Devices Market to Hit $12.31 Billion by 2033, Growing at 12.6% CA …
The Japan wearable devices market reached US$4,026.98 million in 2024 and is expected to reach US$12,310.52 million by 2033, growing at a CAGR of 12.6 % during the forecast period 2025-2033, according to DataM intelligence.
Japan's Wearable Devices Market includes smartwatches, fitness trackers, health monitors, and AR/VR devices. Growth is driven by healthcare monitoring, fitness trends, and IoT adoption. Applications span personal wellness, remote patient monitoring, and industrial safety. Companies and…
Germany Probiotic Drinks Market was US$ 1,006.76 million in 2020 and is expected …
The Germany Probiotic Drinks Market was US$ 1,006.76 million in 2020 and is expected to reach US$ 1,738.01 million in 2028 growing at a CAGR of 7.76% during the forecast period (2025-2028).
Germany's Probiotic Drinks Market includes beverages fortified with live microorganisms promoting gut health and immunity. Growth is driven by wellness trends, functional foods demand, and consumer awareness. Products include yogurts, fermented drinks, and kefir. Retail, health food stores, and…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
